NCT00625495View on ClinicalTrials.gov

Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

November 30, 2002

Study Completion Date

November 30, 2002

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Esomeprazole

40mg Intravenous infusion over 3 minutes

DRUG

Esomeprazole

40mg Oral

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00625495 - Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) | Biotech Hunter | Biotech Hunter